From Concept to Clinic, Circular RNA Faces Its Test

A December 2025 deal between Circurna and uBriGene highlights how circular RNA is shifting from promise to production

6 Feb 2026

RNA medicine is entering a more practical phase. After years of bold claims and early experiments, the focus is shifting toward execution. Few areas capture that shift better than circular RNA.

In December 2025, Circurna and uBriGene announced a strategic partnership aimed at one goal: making circular RNA at GMP scale. The move was less about hype and more about groundwork. It reflects a growing belief that the next breakthroughs in RNA will come from manufacturing discipline as much as molecular design.

Circular RNA is often framed as a step beyond traditional messenger RNA. Its closed-loop structure can improve stability and extend protein expression, features that make it attractive for oncology, rare diseases, and protein replacement therapies. Scientists have been intrigued for years. What has lagged is the ability to produce it reliably and in volumes suitable for clinical use.

That gap is where this partnership fits. Circurna brings its circular RNA platform. uBriGene contributes experience in advanced drug manufacturing. Together, they aim to solve a problem that has quietly slowed the field: how to move circular RNA out of the lab and into regulated production.

uBriGene has emphasized speed and scalability, signaling that industrial readiness now carries as much weight as scientific novelty. This mindset mirrors a broader change across biotech. New modalities are no longer judged only on elegance or promise, but on whether they can survive the realities of quality control, validation, and supply chains.

The timing is notable. Analysts expect RNA therapeutics to grow into a multibillion-dollar market in the next decade, with momentum shifting toward newer formats like circular and self-amplifying RNA. Established companies such as Moderna are also broadening their pipelines beyond vaccines, raising the stakes for emerging platforms to mature quickly.

For circular RNA, challenges remain. Clinical trials have yet to begin, and regulatory paths are still taking shape. Manufacturing investments are costly, and missteps can stall progress.

Still, the direction is clear. Partnerships like this suggest the field is settling into its next chapter. Circular RNA is no longer defined only by what it might do someday. It is being built, methodically, for real-world use.